Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Arcus Biosciences, Inc. (RCUS) has a Wall Street consensus price target of $28.00, based on estimates from 17 covering analysts. With the stock currently trading at $20.37, this represents a potential upside of +37.5%. The company has a market capitalization of $2.55B.
Analyst price targets range from a low of $20.00 to a high of $35.00, representing a 54% spread in expectations. The median target of $29.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, RCUS trades at a trailing P/E of -6.2x. Analysts expect EPS to grow -25.5% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RCUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for RCUS is $28, representing 37.5% upside from the current price of $20.37. With 17 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
RCUS has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $28 implies 37.5% upside from current levels.
RCUS's current price is $20.37 with a consensus target of $28 (37.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $35 for RCUS, while the most conservative target is $20. The consensus of $28 represents the median expectation. These targets typically reflect 12-month expectations.
RCUS is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month RCUS stock forecast based on 17 Wall Street analysts shows a consensus price target of $28, with estimates ranging from $20 (bear case) to $35 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on RCUS, with a "Buy" consensus rating and $28 price target (37.5% upside). 14 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
RCUS analyst price targets range from $20 to $35, a 54% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28 consensus represents the middle ground.